Apnimed priced shares at $16, raising $192M to value the company at $600M+. The pill could receive FDA approval in Q1 2027, targeting 10.5M diagnosed but untreated sleep apnea patients. Sleep apnea affects 80M Americans but only 23M are diagnosed; current CPAP machines are widely rejected. Untreated apnea increases risk of heart disease, stroke, and neurodegenerative conditions.
Sleep Apnea Biotech Apnimed Raises $192M in IPO Ahead of Pill Approval
Untreated sleep apnea affects millions of Americans, increasing their risk of heart disease, stroke, and neurodegenerative diseases like Parkinson's and Alzheimer's.